SRS Capital Advisors Inc. Boosts Stock Position in Danaher Co. (NYSE:DHR)

SRS Capital Advisors Inc. lifted its position in shares of Danaher Co. (NYSE:DHR) by 17.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,671 shares of the conglomerate’s stock after buying an additional 1,153 shares during the period. SRS Capital Advisors Inc.’s holdings in Danaher were worth $1,917,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC grew its stake in shares of Danaher by 20.2% during the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock valued at $2,112,000 after buying an additional 1,533 shares during the last quarter. Caden Capital Partners LP increased its stake in Danaher by 12.4% in the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after purchasing an additional 15,313 shares during the period. JARISLOWSKY FRASER Ltd lifted its position in Danaher by 10.8% in the fourth quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock valued at $132,524,000 after purchasing an additional 55,908 shares during the last quarter. HighPoint Advisor Group LLC bought a new stake in Danaher in the fourth quarter valued at approximately $2,614,000. Finally, Norden Group LLC purchased a new stake in shares of Danaher during the first quarter valued at approximately $4,151,000. Institutional investors own 79.05% of the company’s stock.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,659 shares of company stock valued at $11,042,433. Insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.6 %

NYSE:DHR traded up $1.49 during mid-day trading on Friday, hitting $266.20. 3,324,729 shares of the company’s stock were exchanged, compared to its average volume of 2,790,567. The company has a market cap of $197.17 billion, a PE ratio of 45.12, a P/E/G ratio of 4.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The business has a fifty day moving average price of $261.30 and a 200 day moving average price of $255.73.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.05 EPS. Equities analysts predict that Danaher Co. will post 7.59 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Leerink Partners upped their price target on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Wells Fargo & Company initiated coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price for the company. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Evercore ISI lowered their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Finally, Jefferies Financial Group assumed coverage on Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective on the stock. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.